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Abstract—Hypertension is a common complication in hemodialysis patients during erythropoietin (EPO) treatment. The
underlying mechanisms of EPO-induced hypertension still remain to be determined. Increased transient receptor
potential canonical (TRPC) channels have been associated with hypertension. Now, TRPC gene expression was
investigated using quantitative real-time RT-PCR and immunoblotting in cultured human endothelial cells and in
monocytes from hemodialysis patients. EPO dose-dependently increased TRPC5 mRNA in endothelial cells. EPO
increased TRPC5 mRNA stability, that is, EPO prolonged the half-life period for TRPC5 mRNA from 16 hours (control)
to 24 hours (P0.05). The poly(A) tail length was measured by rapid amplification of cDNA ends-poly(A) test.
Increased TRPC5 mRNA stability was attributed to longer 3 poly(A) tail lengths after EPO administration. EPO also
significantly increased TRPC5 channel protein abundance by 70% (P0.05). Whole-cell patch clamp showed that
angiotensin II–induced, TRPC5-mediated currents were dramatically increased in endothelial cells treated with EPO.
Fluorescent dye techniques confirmed that increased calcium influx after EPO treatment was abolished after TRPC5
knockdown (P0.05). EPO also significantly increased intracellular reactive oxygen species production. Knockdown
of TRPC5 alleviated EPO-induced reactive oxygen species generation in endothelial cells (P0.05). In vivo,
EPO-treated hemodialysis patients showed significantly increased amounts of TRPC5 mRNA in monocytes compared
with EPO-free hemodialysis patients (6.02.4 [n12] versus 1.00.5 [n9]; P0.01). Patients undergoing EPO
treatment also showed significantly elevated systolic blood pressure (1607 versus 1396 mm Hg; P0.05). Our
findings suggest that upregulated functional TRPC5 gene may be one cause of EPO-induced hypertension in patients
with chronic kidney disease. (Hypertension. 2011;58:317-324.)
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Elevated arterial blood pressure is a common adverseeffect of erythropoietin (EPO) administration in patients
and animal models with chronic kidney disease.1–4 Several
observations indicate that EPO-induced hypertension is not
only mediated by changes in erythrocyte mass but also by
direct adverse effects of EPO. The underlying mechanisms of
EPO-induced rise in blood pressure still remain to be deter-
mined.4,5 Considerable evidence has been accumulated for
impaired cellular calcium homeostasis in EPO-associated
hypertension. EPO significantly increases cytosolic free cal-
cium concentration and expands sarcoplasmic calcium stores
in platelets from essential hypertensive or EPO-associated
hypertension patients and cultured vascular smooth muscle
cells from rats.6–8
Transient receptor potential canonical (TRPC) channels are
calcium-permeable nonselective cation channels that had
been identified in many cell types, including endothelial cells
and peripheral blood cells.9 We previously showed signifi-
cantly increased expression of functional TRPC5 channel
protein in patients with essential hypertension and in sponta-
neously hypertensive rats.10–12 In the present study, we
hypothesized that EPO increases the expression and function
of the TRPC5 gene, finally contributing to the pathogenesis
of hypertension. To test this hypothesis, we examined the
effects of EPO on TRPC5 channel expression and function in
cultured human endothelial cells and peripheral blood cells.
Experimental Procedures
Cell Culture
Human umbilical vein endothelial cell–derived EA.hy926 cells
(American Type Culture Collection) were maintained at 37°C and
5% CO2 in DMEM containing 10% FCS, 100 U/mL of penicillin,
and 100 g/mL of streptomycin (BIOCHROM AG, Berlin, Ger-
many). After detachment with 0.25% trypsin, cells were seeded in
plates as appropriate, that is, 6-well plates for RNA and protein
isolation, 12-well plates for patch clamp experiments, and 96-well
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plates for intracellular calcium measurement. All of the experiments
were performed using cells between passages 5 and 8. Cells were
serum starved and incubated with different doses of EPO for 24 to 48
hours, as indicated.
Isolation of RNA and cDNA Synthesis
Total RNA was isolated from cells using the RNeasy minikit
(Qiagen, Hilden, Germany). RNA was used to synthesize first-strand
cDNA using the Transcriptor First Strand cDNA Synthesis kit
(Roche Diagnostics, Mannheim, Germany). PCR was performed
using a reverse transcription mixture consisting of 1 g of total RNA
template, anchored-oligo(dT)18 primer, and transcriptor reverse tran-
scriptase and incubated according to the following procedure, dena-
turation at 65°C for 10 minutes, followed by 50°C for 60 minutes and
heating at 85°C for 5 minutes.
Quantitative Real-Time RT-PCR
Quantitative real-time RT-PCR was performed as described by our
group.13 The primers for coding regions of TRPC type 3 (TRPC3),
type 5 (TRPC5), type 6 (TRPC6), or GAPDH were as follows:
TRPC3 (NM_001130698.1) forward GCGCCGGAGGAGGAG-
GAAG and reverse AGGTCCGGCCCGTGGGAGAA; TRPC5
(NM_012471.2) forward CCACCAGCTATCAGATAAGG and
reverse CGAAACAAGCCACTTATACC; TRPC6 (NM_004621.5)
forward ACGACAGCAGACAATGGCGGTC and reverse CTTC-
CCCATCTTGCTGCATGGAGC; and GAPDH (NM_002046.3)
forward TGTTCGACAGTCAGCCGCATCTTC and reverse
GGTGACCAGGCGCCCAATACG.
Quantitative real-time RT-PCR was performed using FastStart
DNA Master SYBR Green I (Roche Diagnostics). PCR amplification
conditions were 30 to 40 cycles of denaturation at 95°C for 10
seconds, annealing at 60°C for 10 seconds, and extension at 72°C for
15 seconds. After quantification, melting curves were generated with
a heating rate of 0.1°C per second from 65° to 95°C. Data were
recorded on a LightCycler 2.0 Instrument with LightCycler Software
Version 4.0 (Roche Diagnostics). Normalized ratios of gene expres-
sions were calculated as relative expressions of TRPCs normalized to
the GAPDH gene, respectively.
PCR products were size fractionated on 1% agarose gels and were
visualized by ethidium bromide staining using an imaging analyzer
(GelDoc 2000; BioRad Laboratories, Munich, Germany). The ex-
pected product sizes were 164 (TRPC3), 159 (TRPC5), and 109 bp
(TRPC6), respectively.
mRNA Decay Analysis
The effect of EPO on TRPC5 mRNA stability was examined by
inhibiting mRNA transcription using actinomycin D (1 mol/L).
After the cells had been incubated with EPO or vehicle in DMEM
with 1% serum for 10 hours, actinomycin D was added, and the
reduction of TRPC5 mRNA abundance was determined by quanti-
tative real-time RT-PCR.
Rapid Amplification of cDNA Ends-Poly(A) Test
To measure the 3 poly(A) tail lengths of TRPC5 mRNA, rapid
amplification of cDNA ends-poly(A) test was performed using a
commercially available ALL-TAIL kit following the manufacturer’s
instructions (Bioo Scientific, Austin, TX). First, T4-RNA-ligase2
was used to join an adenylated adaptor oligonucleotide 5rAppTT-
TAACCGCGAATTCCAG/3ddC/3 to the 3 end of total RNA.
Next, reverse transcription was performed using a primer specific to
the adenylated adaptor to initiate the production of cDNA. The
primers used for amplification of the poly(A) tail and a short stretch
of the 3 untranslated region of TRPC5 transcripts were forward
AGAACCTGGGCTACATTCCT and reverse CTGGAATTCGCG-
GTTAAA. PCR products were separated on 1.8% agarose gels and
were visualized by ethidium bromide.
Knockdown of TRPC5 by Small Interfering RNA
Endothelial cells were transfected with small interfering RNA
(siRNA) specific for TRPC5 for 48 hours using a silencer siRNA
transfection kit (Ambion, Cambridgeshire, United Kingdom).
Briefly, endothelial cells in DMEM containing 10% FBS were
incubated with siPORT amine (Ambion) and chemically synthesized
siRNA (10 nmol/L; Ambion) specific for TRPC5. The target sequence
for TRPC5 was 5-GGAGGCUGAGAUCUACUAUtt-3 (sense) and
5-AUAGUAGAUCU CAGCCUCCtg-3 (antisense). In control exper-
iments, negative control siRNA (Ambion) that has no significant
homology to any known human gene sequence did not affect TRPC
expression.
Immunoblotting of TRPC5
Immunoblotting was performed as described by our group.10,13 Cells
were washed with ice-cold PBS and were collected in 500 L of
ice-cold lysis buffer containing Tris-HCl (25 mmol/L; pH 8.0), NaCl
(150 mmol/L), EDTA (1 mmol/L), 3-[(3-cholamidopropyl)-
dimethylammo-nio]-1-propane sulfonate (20 mmol/L), phenylmeth-
ane sulfonyl fluoride (1 mmol/L), and complete mini protease
inhibitor mixture (Roche Diagnostics). Proteins were separated by
10% SDS-PAGE at 100 V for 30 minutes followed by 150 V for 60
minutes and transferred to Hybond-ECL nitrocellulose membranes
(NEN Life Science, Boston, MA). Membranes were blocked with
Odyssey blocking buffer (Licor Biosciences, Bad Homburg, Ger-
many) overnight at 4°C. Membranes were incubated with primary
antibodies, that is, rabbit antirat TRPC5 antibody (1:500, Alomone
Labs, Jerusalem, Israel) together with goat antirat GAPDH antibod-
ies (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA) overnight at
4°C. The membranes were washed 3 times with PBS containing
0.1% Tween 20 and were subsequently incubated with secondary
IRDye800CW-infrared fluorescent dye-labeled sheep antirabbit an-
tibodies (1:1000, Biomol, Hamburg, Germany) and Alexa Fluor680-
allophyco cyanin-fluorescence-labeled donkey antigoat antibodies
(1:1000; Invitrogen, Eugene, OR) for 60 minutes at room tempera-
ture with gentle agitation. After washing, imaging was performed
using the Odyssey infrared imaging system (Licor Biosciences) at
810 nm emission with an excitation wavelength of 780 nm and at 700
nm emission with an excitation wavelength of 680 nm. The predicted
molecular weights are 97 kDa for TRPC5 and 37 kDa for GAPDH,
respectively.
Quantitative In-Cell Western Assay of TRPC5
Quantitative in-cell Western assays of proteins were performed using
the Odyssey infrared imaging system (Licor biosciences), as de-
scribed by our group.10,11 Cells were grown on 96-well plates and
fixed by 3.7% formaldehyde. Measurements were performed in
quadruplicate and averaged.
Intracellular Calcium Measurements Using
Fluorescence Spectrophotometry
Endothelial cells were seeded onto 96-well plates and incubated with
the calcium indicator fluo-4AM (5 mol/L) for 60 minutes at room
temperature. Cells were then washed with physiological saline
solution containing 134 mmol/L of NaCl, 6 mmol/L of KCl,
2 mmol/L of CaCl2, 1 mmol/L of MgCl2, 10 mmol/L of glucose, and
10 mmol/L of HEPES (pH 7.4 with NaOH) to remove extraneous
dye. Fluorescence was measured using a fluorescent plate reader
(Victor3, Helsinki, Finland) at 535 nm emission with excitation
wavelength of 485 nm. TRPC was activated by angiotensin II (Ang
II). The amplitudes were expressed as fractional fluorescence in-
crease (F/F0).
Patch Clamp Experiments
Membrane currents were recorded using the whole-cell configuration
of the patch clamp technique as described by our group.14 Experi-
ments were performed at room temperature in the tight-seal whole-
cell configuration of the patch-clamp technique with heat-polished,
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patch pipettes with resistances of 4 to 6 mol/L. Series resistances
were in the range of 10 to 35 mol/L, and seal resistances were in
the range of 1 to 2 G. High-resolution membrane currents were
recorded with an EPC-9 patch-clamp amplifier (HEKA) controlled
by PULSE software on a Power Macintosh computer (G3). High-
resolution currents were low-pass filtered at 2.9 kHz. The reference
electrode was an Ag/AgCl pellet connected to the bath solution
through a 150-mmol/L NaCl/agar bridge. Whole cell currents were
elicited by voltage ramps from120 to120 mV (300-ms duration)
applied every 15 seconds from a holding potential of 40 mV.
Pipettes for whole cell recordings were filled with a solution
composed of 130 mmol/L of CsCH3O3S, 10 mmol/L of CsCl,
2 mmol/L of MgCl2, and 10 mmol/L of HEPES (pH 7.2 with CsOH).
The standard bath solution contained 140 mmol/L of NaCl,
2.8 mmol/L of KCl, 2 mmol/L of CaCl2, 1 mmol/L of MgCl2,
11 mmol/L of glucose, 10 mmol/L of sucrose, and 10 mmol/L of
HEPES (pH 7.4 with NaOH). Ang II (200 nmol/L) was added to the
cell via an application pipette positioned in close proximity to the
cell.
Assessment of Intracellular Reactive
Oxygen Species
Intracellular reactive oxygen species (ROS) generation was assessed
in endothelial cells using 5-(6)-chloromethyl-2,7-dichlorodihydro-
fluorescein diacetate (CM-H2DCFDA), a cell-permeable indicator
for ROS. In brief, endothelial cells were seeded equally in a 96-well
plate and treated with 10 mol/L of CM-H2DCFDA (Invitrogen,
Eugene, OR) for 40 minutes at 37°C in the dark. For cells washing
and loading, the following physiological saline solution was used:
134 mmol/L of NaCl, 6 mmol/L of KCl, 2 mmol/L of CaCl2,
1 mmol/L of MgCl2, 10 mmol/L of glucose, and 10 mmol/L of
HEPES (pH 7.4 with NaOH). Mean fluorescence intensity was
measured using a fluorescent plate reader (Victor3) at 535 nm
emission with excitation wavelength of 485 nm. Untreated cells were
used to determine background fluorescence, which was subtracted
from the treated samples.
Patients
A total of 21 hemodialysis patients (17 men and 4 women; mean age:
632 years; dialysis vintage: 4412 months) were investigated.
Patient history was raised using a standardized questionnaire and was
composed of personal histories, smoking habits, cause of kidney
disease, months of hemodialysis treatment, preexisting cardiovascu-
lar disease (ie, history of myocardial infarction, need for coronary
angioplasty or coronary bypass surgery, ischemic stroke, or periph-
eral vascular disease with the need for amputation or angioplasty),
presence of diabetes mellitus, and current medication, including
angiotensin-converting enzyme inhibitors, ß-blockers, lipid-lowering
agents, or EPO. Blood pressure was measured predialysis after a rest
period of 10 minutes of recumbency. The study was approved by the
local ethics committee. All of the patients gave written, informed
consent. The cause of end-stage renal disease was diabetic nephrop-
athy in 6 cases (28%), nephrosclerosis in 5 cases (24%), chronic
glomerulonephritis in 2 cases (10%), polycystic kidney disease in 1
case (5%), and other/unknown in 7 cases (33%). Angiotensin-
converting enzyme inhibitors were prescribed in 2 cases (10%),
ß-blockers in 13 cases (62%), calcium channel blockers in 3 cases
(14%), and EPO therapy in 12 cases (57%). Mean duration of
hemodialysis at inclusion was 4412 months. All of the patients
were routinely dialyzed for 4 to 5 hours 3 times weekly using
biocompatible membranes with no dialyzer reuse. The dialysates
used were bicarbonate based. All of the patients were ambulatory
and free of acute intercurrent illness. Mean leukocyte count was
9.30.6109/L, mean hemoglobin level 9.90.3 mg/dL, mean
platelet count 25327109/L, serum creatinine 6.50.6 mg/dL,
blood urea 8510 mg/dL, serum albumin 3.30.2 g/L, serum calcium
2.240.05 mmol/L, and serum phosphate 1.710.16 mmol/L. Mean
dose of dialysis (kt/V) was 1.20.1.
Preparation of Monocytes
Human monocytes were prepared using antibody coated superparamag-
netic polystyrene beads coated with a primary monoclonal antibody
specific for the CD14 membrane antigen expressed on human mono-
cytes (Dynal Biotech, Hamburg, Germany). Briefly, mononuclear cells
were obtained from heparinized blood using HISTOPAQUE-1077 and
purified by superparamagnetic polystyrene beads. Cells were then
resuspended in Hanks’ balanced salt solution containing the following:
NaCl, 136 mmol/L; KCl, 5.40 mmol/L; KH2PO4, 0.44 mmol/L;
Na2HPO4, 0.34 mmol/L; D-glucose, 5.6 mmol/L; CaCl2, 1 mmol/L; and
HEPES, 10 mmol/L (pH 7.4).
Materials
Ang II, phosphoinositide 3-kinase (PI3K) inhibitor LY294002,
Rho-associated protein kinase inhibitor Y27632, and mitogen-acti-
vated protein kinase kinase inhibitor PD98059 were purchased from
Sigma-Aldrich (Deisenhofen, Germany). EPO (epoetin-) was pur-
chased from Roche (Mannheim, Germany).
Statistical Analysis
All of the data were expressed as the meanSEM. Comparisons
between groups were analyzed using the Mann-Whitney test or
ANOVA and Bonferroni multiple comparison test as appropriate. A
2-tailed P value 0.05 was considered statistically significant.
Results
Dose-Dependent Effect of EPO on TRPC
mRNA Levels
Using quantitative real-time RT-PCR, we detected TRPC3,
TRPC5, and TRPC6 mRNA in cultured endothelial cells.
PCR products appeared at expected molecular weight on the
agarose gel. Melting analysis confirmed the presence of a
single peak for all 3 of the TRPC channel members (Figure
1A and 1B). Incubation of endothelial cells with EPO for 24
hours resulted in a dose-dependent upregulation of TRPC5
mRNA (Figure 1C). EPO at 100 U/mL significantly increased
TRPC5 mRNA by 79%.
Effect of EPO on TRPC5 mRNA Stability
The increased TRPC5 mRNA could be because of in-
creased mRNA stability. To address this question, we
examined EPO mRNA stability by inhibiting new mRNA
transcription with actinomycin D. After the cells had been
incubated with EPO, actinomycin D (1 mol/L) was
added, and the time-dependent decay of TRPC5 mRNA
was measured by real-time RT-PCR. EPO increased
TRPC5 mRNA stability in endothelial cells, that is, EPO
prolonged the half-life period for TRPC5 mRNA from 16
hours under control conditions to 24 hours after EPO
treatment (each n3; P0.05; Figure 1D).
Identification of TRPC5 mRNA With Long
Poly(A) Tails With Rapid Amplification of cDNA
Ends-Poly(A) Test
The 3 poly(A) tail plays an important role in determining
mRNA stability. Longer 3 poly(A) tail length causes in-
creased mRNA stability because of reduced degradation.
Thus, we examined the 3 poly(A) tail lengths of the TRPC5
mRNA in endothelial cells treated with or without EPO. As
shown in Figure 1E, EPO increased 3 poly(A) tail lengths of
TRPC5 mRNA, as indicated by separating PCR products on
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agarose gels. In endothelial cells exposed to EPO for 48
hours, there was a significant increase in the ratio of long
(	200-bp bands) to short (	150-bp bands) poly(A) of
TRPC5 fragments (2.80.4 versus 1.00.1; each n4;
P0.05).
Effect of EPO on TRPC5 Protein Expression
To confirm that the increased TRPC5 mRNA abundance
facilitated gene translation, we investigated TRPC5 protein
abundance using both immunoblotting and quantitative in cell
Western techniques. In accordance with transcripts data,
TRPC5 protein expression was also significantly higher in
endothelial cells after incubation with EPO (100 U/mL) for
48 hours compared with control (1.00.1 versus 1.70.1;
each n4; P0.05; Figure 2).
Effect of EPO on TRPC5-Mediated Currents and
Calcium Influx
Patch clamp studies indicated that Ang II (200 nmol/L) could
induce TRPC-like channel-mediated currents in endothelial
cells (Figure 3A). Cells pretreated with EPO for 48 hours
exhibited a pronounced increase in such currents, whereas
cell capacitance was unchanged. Furthermore, Ang II–in-
duced calcium influx was significantly increased in EPO-
treated endothelial cells compared with control conditions
(EPO 1.10.1 versus control 0.50.1; each n5; P0.05).
After TRPC5 knockdown, the increased calcium influx after
EPO treatment was abolished (siRNA against TRPC5 plus
EPO, 0.60.1; each n5; P0.05 compared with EPO
alone; Figure 3B and 3C).
Inhibition of PI3K Attenuates the EPO-Enhanced
Ang II–Induced Calcium Influx
As shown in Figure 3D, the enhanced Ang II–induced
calcium influx after EPO was blocked in the presence of the
PI3K inhibitor LY294002. On the other hand, Rho-associated
protein kinase inhibitor Y27632 and mitogen-activated pro-
tein kinase kinase inhibitor PD98059 did not affect the Ang
II–induced calcium influx after EPO.
Effect of EPO on Intracellular ROS Generation in
Endothelial Cells
As shown in Figure 3E, incubation of EPO in endothelial
cells for 48 hours significantly increased ROS generation by
70% compared with the control (EPO: 1.70.1; control:
1.00.1; each n4; P0.05). After TRPC5 knockdown, the
EPO-induced intracellular ROS production was not signifi-
cantly different compared with control conditions (each n4;
P
0.05). There was no significant difference between the
EPO-free control and EPO-free control treated with negative
control siRNA, which has no significant homology to any
known human gene sequence.
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Figure 1. Erythropoietin (EPO) upregulates transient receptor potential canonical (TRPC) 5 mRNA but not TRPC3 nor TRPC6 in endo-
thelial cells. A, Gel electrophoresis of PCR products from mRNA of TRPC3, TRPC5, and TRPC6. RT indicates RNA without reverse
transcriptase; RNA, no RNA with reverse transcriptase. Marker denotes 100-bp ladder. B, Melting analysis after amplification of
TRPC3, TRPC5, and TRPC6. Melting curve and melting peak are shown. C, Dose-dependent upregulation of TRPC5 mRNA by EPO.
Bar graph gives the normalized ratio of TRPC expression vs GAPDH expression (each n3). D, TRPC5 mRNA stability was estimated
by inhibition of gene transcription with actinomycin D (1 mol/L). Data are means of 3 separate experiments. Lines were significantly
different (ANOVA and posttest for linear trend, P0.01). E, Rapid amplification of cDNA ends-poly(A) test (RACE-PAT) results. Ethidium
bromide staining of PCR products separated on 1.8% agarose gels showing increased length of poly(A) tail of TRPC5 mRNA in EPO-
treated samples. Bar graph summarizing densitometric data expressing the ratio of long poly(A) TRPC5 (	200-bp bands) to short
poly(A) TRPC5 (	150-bp bands) (n4).
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Effect of Long-Term EPO Treatment on TRPC5
mRNA Levels and Blood Pressure in
Hemodialysis Patients
EPO-treated hemodialysis patients showed significantly in-
creased amounts of TRPC5 mRNA in monocytes compared
with EPO-free hemodialysis patients (EPO-treated, 6.02.4
[n12] versus EPO-free, 1.00.5 [n9]; P0.05; Figure 4A).
Patients undergoing EPO treatment also showed significantly
elevated systolic blood pressure (EPO-treated, 1607 mm Hg
[n12] versus EPO-free, 1396 mm Hg [n9]; P0.05; Fig-
ure 4B). On the other hand, clinical and biochemical data were
not significantly different between EPO-treated and EPO-free
hemodialysis patients (age: 624 years [n12] versus 654
years [n9]; dialysis vintage: 4918 months versus 3112
months; leukocytes: 9.70.8109/L versus 8.90.9109/L;
hemoglobin: 9.70.5 g/dL versus 10.30.5 g/dL; platelets:
24437109/L versus 26539109/L; serum creatinine:
6.60.8 mg/dL versus 6.41.1 mg/dL; blood urea: 7615
mg/dL versus 10214 mg/dL; serum albumin: 3.10.2 mg/dL
versus 3.30.3 mg/dL; serum calcium: 2.260.07 mmol/L versus
2.220.07 mmol/L; serum phosphate: 1.650.20 mmol/L versus
1.810.30 mmol/L; each P
0.05 between the groups).
Discussion
In the present study we showed that EPO increases TRPC5
gene expression and function. Treatment with EPO resulted
in a dose-dependent increase in TRPC5 mRNA by enhancing
TRPC5 mRNA stability via increased 3 polyadenylation.
Consequentially, upregulated TRPC5 protein abundance was
accompanied by increased currents, calcium influx, and
enhanced oxidative stress in endothelial cells.
EPO is a well-known growth factor causing maturation of
erythroblasts. EPO receptors have been identified in several
cell types, including endothelial cells.15,16 In the literature
there are several examples showing that EPO can increase
gene expression in several tissues.17–19 d’Uscio et al17 showed
that EPO increased the expression of copper- and zinc-
containing superoxide dismutase in vascular tissue. Grossi et
al18 showed that EPO upregulates the expression of the EPO
receptor in a TF-1 cell line. As reported by Acquaviva et al,19
EPO administration enhanced frataxin protein in primary
fibroblasts.
Results from RT-PCR using subtype-specific primers in-
dicate that TRPC3, TRPC5, and TRPC6 were expressed in
endothelial cells. Our results showed that EPO selectively
increases TRPC5 but not TRPC3 or TRPC6 mRNA in a
dose-dependent manner. The specific EPO-TRPC5 interac-
tion underscores TRPC subtype-specific characteristics of
TRPC5 compared with TRPC3 and TRPC6. Based on their
different structure, TRPC5 belongs to the TRPC4/5 subfam-
ily, whereas TRPC3 and TRPC6 belong to TRPC3/6/7
subfamily.9 Furthermore, these TRPC channels show differ-
ent electrophysiological characteristics. TRPC5 channels can
be activated by lanthanum (La3) and do not respond to
diacylglycerol. By contrast, TRPC3 and TRPC6 channels are
inhibited by micromolar concentrations of La3 and can be
activated by diacylglycerol.9,20 We showed that EPO in-
creases TRPC5 mRNA by enhancing its stability. A long 3
poly(A) tail is important for mRNA stabilization. A long 3
poly(A) tail facilitates binding of multiple poly(A) binding
protein molecules, which protects against ribonucleolytic
attack and allows mRNA-ribosome interactions.21,22 Using
the rapid amplification of cDNA ends-poly(A) test we ob-
served that EPO increased TRPC5 mRNA with long 3
poly(A) tails. These findings shed light on a novel mechanism
by which EPO affects gene transcription. We also showed
that increased TRPC5 mRNA caused increased TRPC5 pro-
tein abundance. Taken together, we provide direct evidence
that EPO upregulates TRPC5 gene expression at both tran-
scriptional and translational levels, likely because of in-
creased polyadenylation in the 3 poly(A) tail of TRPC5
mRNA.
We further investigated the functional consequences of
increased expression of the TRPC5 gene. Our in vitro studies
indicated that the administration of EPO increased TRPC5-
mediated currents and calcium influx in endothelial cells.
Altered TRPC channel function may contribute to hyperten-
sion. TRPC5 channels are nonselective cationic channels that
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Figure 2. Erythropoietin (EPO) upregulates transient receptor
potential canonical (TRPC) 5 channel proteins. A, Immunoblot-
ting of TRPC5 and GAPDH in endothelial cells treated with vehi-
cle (control) or with EPO. B, Representative immunofluores-
cence assay (top) and summary data (bar graph) showing the
expression of TRPC5 channel proteins normalized to GAPDH
proteins. Blank indicates omitting primary antibodies. For the
representative immunofluorescence experiment, measurements
were performed in quadruplicate. This experiment was repeated
2 times. *P0.05 vs control.
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can be activated by G protein–coupled receptors.23 Several
reports showed an increased agonist-induced calcium influx
in hypertension.10–12 In line with previous reports, we show
that Ang II induced a strong increase of calcium influx
through TRPC-like channels in endothelial cells. Further-
more, Ang II–induced calcium influx was significantly atten-
uated after specific TRPC5 knockdown using gene silence
techniques. The TRPC5-mediated calcium influx underlies a
key signaling mechanism that stimulates the calcium-
dependent release of several endothelium-derived vasocon-
strictive agents, including endothelin, urotensin, or epoxyei-
cosatrienoic acids, which contributes to the development of
hypertension.24–26 A recent study also showed that TRPC5 is
activated by pressure-induced membrane stretch associated
with hypertension.27
EPO has been shown to initiate a cascade of downstream
signaling pathways, for example, PI3K, Rho-associated pro-
tein kinase, and mitogen-activated protein kinase, to affect
endothelial cell function.28–31 Our data showed that the
enhanced Ang II–induced calcium influx in EPO-treated cells
could be blocked by the PI3K inhibitor LY294002 but not by
Rho-associated protein kinase inhibitor Y27632 or mitogen-
activated protein kinase inhibitor PD98059. These data are
consistent with previous reports showing growth factors
induced incorporation of functional TRPC5 channels in a
PI3K-dependent manner.32
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Figure 3. Erythropoietin (EPO) affects transient receptor potential canonical (TRPC) 5–associated calcium influx and reactive oxy-
gen species (ROS) generation in cultured endothelial cells. A, TRPC-like currents in endothelial cells pretreated with vehicle (con-
trol) or EPO. To exclude potassium channel currents, pipettes for whole cell recordings were filled with solution containing
cesium. B, Immunoblots confirming knockdown of TRPC5 channel proteins using gene silence techniques. Control indicates neg-
ative control small interfering RNA (siRNA) that has no significant homology to any known human gene sequence. C, Representa-
tive recordings and summary data (bar graph) of Ang II–induced calcium influx. siRNAEPO indicates siRNA against TRPC5 plus
EPO; control indicates negative control siRNA that has no significant homology to any known human gene sequence. *P0.05. D,
Inhibition of the phosphoinositide 3-kinase (PI3K) using LY294002 attenuated calcium influx in EPO-treated cells. n5 in each
group. *P0.05. E, Measurement of intracellular ROS generation in cultured endothelial cells. Cells were subject to EPO treatment
for 48 hours. Cells were then loaded with the intracellular fluoroprobe CM-H2DCFDA (10 mol/L), and fluorescence intensity was
measured. Intracellular ROS formation was expressed as the mean fluorescence intensity and normalized to control. Experiments
were performed in quadruplicate. *P0.05.
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Using the fluorescent dye techniques, we observed that
endothelial cells incubated with exogenous EPO showed
enhanced oxidative stress, as indicated by increased intracel-
lular ROS production. These findings are supported by
several studies, showing that EPO generates significant oxi-
dative stress and oxidant damage both in vivo and in
vitro.33–35 We have further shown that knockdown of TRPC5
is accompanied by reduced intracellular ROS production,
which was induced by EPO in endothelial cells. Recently, it
was reported that agonist-stimulated cytosolic calcium in-
crease is followed by an increase in ROS formation in
endothelial cells.36 Because TRPC5 channels are calcium
permeable, elevated agonist-stimulated calcium influx
through upregulated TRPC5 channels in endothelial cells
during EPO treatment may contribute to the ROS formation,
which underlies pathogenesis of EPO-induced hypertension.
The present results may put light on the mechanisms
underlying development of hypertension during EPO treat-
ment in hemodialysis patients. Large clinical studies uncov-
ered that elevated blood pressure is a frequent adverse effect
of EPO treatment.1–3 In line with these findings we gave
evidence that hemodialysis patients treated with EPO had
higher systolic blood pressure. Furthermore, these patients
had significantly increased expression of TRPC5 compared
with EPO-free hemodialysis patients. These in vivo findings
support our in vitro results, showing that EPO treatment
upregulates TRPC5 expression. Together, TRPC5 may act as
an essential downstream effector molecule for EPO signaling
and may contribute to the hypertensive adverse effects
observed during EPO therapy. In the present study we
investigated TRPC5 expression in peripheral blood cells from
hemodialysis patients without and with EPO administration.
However, it is not presently known whether similar effects of
EPO on TRPC5 expression can also be observed in the
patient vasculature.
In conclusion, we demonstrate that EPO stabilizes TRPC5
mRNA, increases TRPC5 protein expression, and augments
TRPC5-mediated currents and calcium influx in endothelial
cells. EPO-induced oxidative stress can also be attenuated by
knockdown of TRPC5. Finally, an increased TRPC5 mRNA
is associated with elevated blood pressure in hemodialysis
patients during EPO therapy.
Perspectives
The goal of EPO treatment is to increase hematocrit and
hemoglobin in dialysis patients. However, hypertension is
frequently observed during such treatment. The extent of the
rise in blood pressure has been shown to correlate with
increased hematocrit, as well as increased risk of mortality
and cardiovascular events. Thus, the definite mechanisms of
EPO-associated hypertension need to be determined.
TRPC channels are calcium-permeable nonselective cation
channels that had been identified in endothelial cells and
peripheral blood cells. Many investigators have shown that
significantly increased TRPC channel protein is associated
with hypertensive events in both human and animal models.
The present study unveils a novel mechanism by which EPO
affects TRPC gene transcription. EPO administration facili-
tates the translation of TRPC5 gene by prolonging the 3
poly(A) tail of TRPC5 transcripts. Furthermore, these TRPC5
channel proteins are functional, as confirmed by TRPC5-
mediated increased currents, increased calcium influx, and
enhanced oxidative stress in endothelial cells. EPO-induced
above effects can be eliminated by knockdown of TRPC5
using gene silence techniques. Our in vitro findings are also
supported by our in vivo data, showing that hemodialysis
patients treated with EPO had higher systolic blood pressure
and significantly increased expression of TRPC5 compared
with EPO-free hemodialysis patients. We, therefore, specu-
late that upregulated TRPC5 might have functional relevance
in the pathogenesis of EPO-associated hypertension in pa-
tients with chronic kidney disease. The TRPC5-mediated
calcium influx underlies a key signaling event that stimulates
not only the calcium-dependent release of several endotheli-
um-derived vasoconstrictive agents, for example, endothelin,
urotensin, or epoxyeicosatrienoic acids, but also calcium-
dependent generation of ROS. These mediators can contrib-
ute to the development of hypertension.
Future studies should examine the effects of EPO, for
example, on the intact endothelium in humans. Presently
there is no drug available for humans that specifically blocks
TRPC5 channels. When novel drugs blocking TRPC5 activity
are available, they should be tested in a model of EPO-
induced hypertension for further validation of the observed
mechanisms.
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